Malignant peripheral nerve sheath tumors: a report from children's oncology group study ARST0332
Topic overview
Children's Oncology Group study of 58 pediatric MPNST patients treated with risk-adapted surgery, chemotherapy, and radiation achieved 87% 5-year survival in low-risk disease but 0% in metastatic cases. NF-1 status did not impact outcomes, while complete resection and absence of metastases were key prognostic factors.
Key takeaways
- Complete surgical resection (R0/R1) is the most critical prognostic factor for MPNST survival regardless of timing.
- Low-risk MPNST patients achieved 87% 5-year EFS with risk-adapted therapy; high-risk metastatic disease had 0% 5-year EFS.
- Neoadjuvant ifosfamide/doxorubicin showed limited efficacy with only 23% objective response rate in evaluable patients.
- NF-1 germline status did not significantly impact event-free or overall survival in this cohort.
- Novel therapeutic approaches are urgently needed for metastatic MPNST given universally poor outcomes with current protocols.
Comments